Crosstalk between EphA2 and BRaf/CRaf is a Key Determinant of Response to Dasatinib

PURPOSE: EphA2 is an attractive therapeutic target due to its diverse roles in cancer growth and progression. Dasatinib is a multi-kinase inhibitor that targets EphA2 and other kinases. However, reliable predictive markers and a better understanding of the mechanisms of response to this agent are ne...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Huang, Jie, Hu, Wei, Bottsford-Miller, Justin, Liu, Tao, Han, Hee Dong, Zand, Behrouz, Pradeep, Sunila, Roh, Ju-Won, Thanapprapasr, Duangmani, Dalton, Heather J., Pecot, Chad V., Rupaimoole, Rajesh, Lu, Chunhua, Fellman, Bryan, Urbauer, Diana, Kang, Yu, Jennings, Nicholas B., Huang, Li, Deavers, Michael T., Broaddus, Russell, Coleman, Robert L., Sood, Anil K.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2014
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3975695/
https://ncbi.nlm.nih.gov/pubmed/24486585
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-13-2141
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia